OTCMKTS:CPMV Mosaic ImmunoEngineering (CPMV) Stock Price, News & Analysis $0.64 0.00 (0.00%) As of 07/10/2026 Add Compare Share Share Stock Analysis Stock AnalysisChartEarningsSEC FilingsBuy This Stock About Mosaic ImmunoEngineering Stock (OTCMKTS:CPMV) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get CPMV alerts:Sign Up Key Stats Today's Range$0.64▼$0.6450-Day Range$0.33▼$0.7552-Week Range$0.31▼$1.05Volume2 shsAverage Volume23 shsMarket Capitalization$4.62 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Mosaic ImmunoEngineering (OTCMKTS:CPMV) is a development-stage biotechnology company focused on advancing immunotherapies and vaccine candidates through its proprietary nanoparticle platform. The company leverages virus-like particles derived from the cowpea mosaic virus (CPMV) to serve as both antigen carriers and immune stimulators, aiming to enhance the magnitude and durability of immune responses. By engineering these plant-based VLPs to display target antigens or adjuvant properties, Mosaic ImmunoEngineering seeks to create differentiated candidates for oncology indications and infectious disease prevention. Operating out of the United States, Mosaic ImmunoEngineering is currently in preclinical stages of development. While detailed pipeline disclosures remain limited, the company highlights its platform’s flexibility to deliver protein antigens in a highly multivalent format, potentially improving efficacy over traditional formulations. Though still early in its corporate history, Mosaic ImmunoEngineering’s approach reflects growing interest in novel nanoparticle-based vaccine technologies, with the company positioning itself to explore collaborations or licensing arrangements as its candidates advance.AI Generated. May Contain Errors. Read More Mosaic ImmunoEngineering Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks1st Percentile Overall ScoreCPMV MarketRank™: Mosaic ImmunoEngineering scored higher than 1% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for Mosaic ImmunoEngineering. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Mosaic ImmunoEngineering is -7.10, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Mosaic ImmunoEngineering is -7.10, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted0.10% of the float of Mosaic ImmunoEngineering has been sold short.Short Interest Ratio / Days to CoverMosaic ImmunoEngineering has a short interest ratio ("days to cover") of 443, which indicates bearish sentiment.Change versus previous monthShort interest in Mosaic ImmunoEngineering has recently decreased by 0.30%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldMosaic ImmunoEngineering does not currently pay a dividend.Dividend GrowthMosaic ImmunoEngineering does not have a long track record of dividend growth. News and Social Media0.0 / 5News Sentiment0.00 News Coverage This WeekMarketBeat has tracked 2 news articles for Mosaic ImmunoEngineering this week, compared to 0 articles on an average week. Company Ownership0.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Mosaic ImmunoEngineering insiders have not sold or bought any company stock.Percentage Held by Insiders80.99% of the stock of Mosaic ImmunoEngineering is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsMosaic ImmunoEngineering has minimal institutional ownership at this time.Read more about Mosaic ImmunoEngineering's insider trading history. Receive CPMV Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Mosaic ImmunoEngineering and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CPMV Stock News HeadlinesMosaic ImmunoEngineering Delays Annual 10-K Filing3 hours ago | theglobeandmail.comMosaic ImmunoEngineering (OTCMKTS:CPMV) and Exicure (NASDAQ:XCUR) Financial SurveyJuly 8, 2026 | americanbankingnews.comTrump’s secret China dealTrump just returned from Beijing with the most powerful business delegation in American history - Elon Musk, Jensen Huang, Tim Cook, and the CEOs of BlackRock, Goldman Sachs, and CitiBank. The media covered the handshakes. But what was really being negotiated behind closed doors? Porter Stansberry has connected the Beijing trip to a landmark pact signed by 13 nations in Washington - a pact designed to cut China out of a $3 trillion investment wave tied to the most critical resource of the 21st century. His new documentary exposes the five assets at the center of it all.July 12 at 1:00 AM | Porter & Company (Ad)Mosaic ImmunoEngineering, Inc. (CPMV) - Yahoo FinanceJune 27, 2025 | au.finance.yahoo.comMosaic ImmunoEngineering, Inc. (CPMV)November 17, 2024 | finance.yahoo.comMosaic Co.November 5, 2024 | wsj.comMosaic ImmunoEngineering (OTC:CPMV) Stock Quotes, Forecast and News SummaryOctober 7, 2024 | benzinga.comCowpea Mosaic Virus Nanoparticles Show Promise in Preventing Metastatic CancersMay 14, 2024 | msn.comSee More Headlines CPMV Stock Analysis - Frequently Asked Questions How have CPMV shares performed this year? Mosaic ImmunoEngineering's stock was trading at $0.3110 at the beginning of 2026. Since then, CPMV stock has increased by 105.4% and is now trading at $0.6388. How were Mosaic ImmunoEngineering's earnings last quarter? Mosaic ImmunoEngineering Inc. (OTCMKTS:CPMV) issued its quarterly earnings results on Wednesday, May, 20th. The company reported ($0.02) EPS for the quarter. How do I buy shares of Mosaic ImmunoEngineering? Shares of CPMV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Mosaic ImmunoEngineering own? Based on aggregate information from My MarketBeat watchlists, some other companies that Mosaic ImmunoEngineering investors own include BioNxt Solutions (BNXTF), Defense Metals (DFMTF), C3.ai (AI), Agile Therapeutics (AGRX), AgriFORCE Growing Systems (AGRI) and Company Calendar Last Earnings5/20/2026Today7/12/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolOTCMKTS:CPMV CIK836564 Webwww.ptsc.com Phone(657) 208-0890Fax760-547-2705Employees3Year FoundedN/AProfitability EPS (Trailing Twelve Months)($0.09) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$690 thousand Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-1,908.81% Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($1.03) per share Price / Book-0.62Miscellaneous Outstanding Shares7,240,000Free Float1,377,000Market Cap$4.62 million OptionableNot Optionable Beta-0.92 7 Best Space Stocks to Own in 2026The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free Report This page (OTCMKTS:CPMV) was last updated on 7/12/2026 by MarketBeat.com Staff. From Our PartnersSpaceX is chump change compared to Elon’s $20T ‘iPhone’Early Apple investors saw peak gains as high as 7,537% after the iPhone launched. Now, multiple insider source...StocksToTrade | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredRay Dalio: Buy Gold. Get Paid.Ray Dalio, founder of Bridgewater Associates, is urging investors to hold 15% of their portfolio in gold and c...Investors Alley | SponsoredThey told you not to miss this oneThe largest companies in the SP 500 are now more overvalued relative to fundamentals than they were at the abs...Thor Metals | SponsoredThe Starlink of EnergyA portable energy unit - already used by the U.S. Navy for decades - is now drawing serious attention from Big...Monument Traders Alliance | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredNow that SpaceX is public, buy this ticker (no, not SpaceX or Tesla)The SpaceX IPO wasn't the big trade - according to Larry Benedict, founder of The Opportunistic Trader, it was...Brownstone Research | SponsoredIs the fix for AI's runaway power problem your golden ticket?The government just committed $200 billion to building computer chips on American soil - one of the largest te...Eagle Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Mosaic ImmunoEngineering Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Mosaic ImmunoEngineering With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
